CALTCalliditas Therapeutics AB

Nasdaq calliditas.se


$ 38.72 $ 0.23 (0.6 %)    

Wednesday, 17-Jul-2024 12:23:36 EDT
QQQ $ 479.98 $ -5.52 (-1.14 %)
DIA $ 409.40 $ -1.73 (-0.42 %)
SPY $ 554.35 $ -3.99 (-0.71 %)
TLT $ 93.63 $ -0.03 (-0.03 %)
GLD $ 226.87 $ -0.84 (-0.37 %)
$ 38.84
$ 38.72
$ 0.00 x 0
$ 0.00 x 0
$ 38.72 - $ 38.72
$ 15.25 - $ 41.90
5,444
na
2.31B
$ 0.92
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

The clinical trial is a bridging study requiring a limited number of Japanese patients to participate in a study similar in des...

 citigroup-downgrades-calliditas-therapeutics-to-neutral-announces-39-price-target

Citigroup analyst Yigal Nochomovitz downgrades Calliditas Therapeutics (NASDAQ:CALT) from Buy to Neutral and announces $39 p...

 jefferies-downgrades-calliditas-therapeutics-to-hold-lowers-price-target-to-39

Jefferies analyst Maury Raycroft downgrades Calliditas Therapeutics (NASDAQ:CALT) from Buy to Hold and lowers the price targ...

 stifel-downgrades-calliditas-therapeutics-to-hold-lowers-price-target-to-40

Stifel analyst Annabel Samimy downgrades Calliditas Therapeutics (NASDAQ:CALT) from Buy to Hold and lowers the price target ...

 asahi-kasei-makes-11b-offer-for-swedish-drugmaker-calliditas-therapeutics-enhancing-pharma-growth-strategy

Asahi Kasei's $1.1 billion acquisition of Calliditas Therapeutics offers 208 SEK per share in cash. The deal boosts Asahi K...

 hc-wainwright--co-downgrades-calliditas-therapeutics-to-neutral-announces-39-price-target

HC Wainwright & Co. analyst Arthur He downgrades Calliditas Therapeutics (NASDAQ:CALT) from Buy to Neutral and announces...

 calliditas-therapeutics-board-unanimously-recommends-acceptance-of-asahi-kaseis-sek-1116b-tender-offer

STOCKHOLM, May 28, 2024 /PRNewswire/ -- The Board of Directors of Calliditas Therapeutics AB (publ) unanimously recommends that...

 hc-wainwright--co-maintains-buy-on-calliditas-therapeutics-lowers-price-target-to-45

HC Wainwright & Co. analyst Arthur He maintains Calliditas Therapeutics (NASDAQ:CALT) with a Buy and lowers the price ta...

 calliditas-therapeutics-q1-eps-088-down-from-033-yoy-sales-2843m-up-from-1832m-yoy

Calliditas Therapeutics (NASDAQ:CALT) reported quarterly losses of $(0.88) per share. This is a 163.47 percent decrease over lo...